Project description
Innovative toolbox platform for Alzheimer’s disease prevention
Alzheimer’s disease (AD), the leading cause of dementia, poses a significant global health challenge, impacting 55 million people worldwide. The escalating number of individuals at risk for AD dementia in Europe underscores a crucial unmet public health need, placing a substantial burden on European economies, healthcare and social care systems. Despite these challenges, effective prevention and early detection strategies are currently lacking. In this context, the EU-funded AD-RIDDLE project aims to revolutionise the detection, diagnosis, prevention and treatment of AD across healthcare settings (HCS). The project will introduce a toolbox platform concept, offering validated tools at each critical step. This approach enables HCS and practitioners to effectively manage enhanced AD care across diverse patient populations.
Objective
Alzheimer's disease (AD), the main cause of dementia, is one of the major global health challenges of our time. This disabling disorder affects 55 million people worldwide, with costs above $1.3 trillion. With 67 million people at risk for AD dementia (prodromal and preclinical AD) in Europe alone, it is a major unmet public health need, with increasing burden for European economies, healthcare and social care systems and a concern for the future. Yet, prevention and early detection strategies have been lacking. Recent advances in disease-modifying therapies and the huge potential benefits of preventive multidomain interventions based on modifiable lifestyle and vascular factors (prevention potential ~ 40%) provide new opportunities. New developments in blood-based biomarkers (BBMs) and digital cognitive tests enable broader, cost-effective testing. The AD-RIDDLE platform is envisioned to revolutionize how AD is detected and diagnosed, prevented and treated across healthcare settings (HCS). AD-RIDDLE centres around a toolbox platform concept, providing a series of validated tools at each key step to enable HCS and practitioners to deploy enhanced AD management across diverse patient populations.
The AD-RIDDLE toolbox platform will include a) community outreach tools to increase awareness/activation on AD prevention; b) combination of easily available, clinically validated biomarkers: digital cognitive tools and BBMs, for early detection of AD dementia risk; c) validated algorithms supporting clinical decisions, to identify people who can benefit from specific preventive therapies (pharma and/or non-pharma) using precision prevention approach. The toolbox usability and efficacy with be tested in real-world settings. We expect that the AD-RIDDLE modular and flexible design can facilitate broad uptake from different healthcare systems, and its tools can advance research to develop cost-effective preventive therapies for AD, with scalability for other dementias
Fields of science
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Funding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
104 22 Stockholm
Sweden
See on map
Participants (20)
17177 Stockholm
See on map
102 26 Stockholm
See on map
405 30 Goeteborg
See on map
22100 Lund
See on map
70211 KUOPIO
See on map
1081 HV Amsterdam
See on map
6200 MD Maastricht
See on map
08005 Barcelona
See on map
28006 Madrid
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1736 SENNINGERBERG
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
60069 LINCOLNSHIRE
See on map
06123 Perugia
See on map
98033 Kirkland
See on map
1204 GENEVE
See on map
33100 Tampere
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
9052 Zwijnaarde Gent
See on map
94250 GENTILLY
See on map
63110 ST LOUIS
See on map
39104 MAGDEBURG
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
CB25 9TU Cambridge
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (3)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
LE1 7RH Leicester
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
SW7 2AZ LONDON
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
M1 4BT Manchester
See on map